Bone drug tested to shield young transplant survivors from fractures
NCT ID NCT07375290
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests whether giving a bone-strengthening drug called zoledronate soon after a stem cell transplant can safely prevent bone loss and fractures in children. Researchers will enroll 20 children aged 5 to 18 who are at high risk for bone problems. The goal is to see if the drug is safe and practical to use in this setting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC STEM CELL TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cincinnati Children's Hospital Medical Center
RECRUITINGCincinnati, Ohio, 45229, United States
Contact Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a safer dose of an old drug shield vulnerable children from deadly fungal infections?
- Could virtual reality help patients recover faster from cell therapy?
- Tailored drug dosing may cut infections after stem cell transplants
- Herbal granules aim to lift mood in transplant survivors
- Can a phone buddy help caregivers of stem cell patients? new study aims to find out.
- New study tracks immune cell function after stem cell transplants to personalize care